Teleflex TFX is gearing as much as announce its quarterly earnings on Thursday, 2024-10-31. This is a fast overview of what buyers ought to know earlier than the discharge.
Analysts are estimating that Teleflex will report an earnings per share (EPS) of $3.39.
Buyers in Teleflex are eagerly awaiting the corporate’s announcement, hoping for information of surpassing estimates and optimistic steerage for the following quarter.
It is price noting for brand new buyers that inventory costs will be closely influenced by future projections relatively than simply previous efficiency.
Overview of Previous Earnings
The corporate’s EPS beat by $0.09 within the final quarter, resulting in a 0.5% improve within the share value on the next day.
This is a have a look at Teleflex’s previous efficiency and the ensuing value change:
Quarter | Q2 2024 | Q1 2024 | This autumn 2023 | Q3 2023 |
---|---|---|---|---|
EPS Estimate | 3.33 | 3.07 | 3.26 | 3.27 |
EPS Precise | 3.42 | 3.21 | 3.38 | 3.64 |
Value Change % | 1.0% | 2.0% | 0.0% | 1.0% |
Analyst Opinions on Teleflex
For buyers, greedy market sentiments and expectations within the trade is important. This evaluation explores the newest insights relating to Teleflex.
The consensus ranking for Teleflex is Outperform, based mostly on 6 analyst scores. With a median one-year value goal of $264.5, there is a potential 11.87% upside.
Understanding Analyst Rankings Amongst Friends
On this comparability, we discover the analyst scores and common 1-year value targets of Globus Medical, Penumbra and Glaukos, three outstanding trade gamers, providing insights into their relative efficiency expectations and market positioning.
- As per analysts’ assessments, Globus Medical is favoring an Outperform trajectory, with a median 1-year value goal of $80.43, suggesting a possible 65.98% draw back.
- The prevailing sentiment amongst analysts is an Purchase trajectory for Penumbra, with a median 1-year value goal of $230.67, implying a possible 2.44% draw back.
- The prevailing sentiment amongst analysts is an Purchase trajectory for Glaukos, with a median 1-year value goal of $141.86, implying a possible 40.0% draw back.
Friends Comparative Evaluation Abstract
The peer evaluation abstract offers a snapshot of key metrics for Globus Medical, Penumbra and Glaukos, illuminating their respective standings inside the trade. These metrics supply priceless insights into their market positions and comparative efficiency.
Firm | Consensus | Income Development | Gross Revenue | Return on Fairness |
---|---|---|---|---|
Teleflex | Outperform | 0.87% | $416.46M | 1.77% |
Globus Medical | Outperform | 115.93% | $369.65M | 0.80% |
Penumbra | Purchase | 14.49% | $162.83M | -5.09% |
Glaukos | Purchase | 19.02% | $73.14M | -9.06% |
Key Takeaway:
Teleflex ranks on the high for Gross Revenue and Return on Fairness amongst its friends. It’s within the center for Income Development.
Discovering Teleflex: A Nearer Look
Teleflex is a Wayne, Pennsylvania-based producer of hospital provides and medical gadgets primarily within the bloodstream/vascular and surgical areas. The agency experiences outcomes throughout seven segments: vascular entry (24% of 2023 gross sales), interventional (17%), anesthesia (13%), surgical (14%), interventional urology (11%), original-equipment manufacturing (11%), and different (10%). Geographic publicity for the enterprise is primarily within the US, which accounts for 60% of income, with worldwide markets making up the rest.
Teleflex’s Monetary Efficiency
Market Capitalization Views: The corporate’s market capitalization falls under trade averages, signaling a comparatively smaller dimension in comparison with friends. This positioning could also be influenced by elements similar to perceived development potential or operational scale.
Income Development: Over the three months interval, Teleflex showcased optimistic efficiency, reaching a income development price of 0.87% as of 30 June, 2024. This displays a considerable improve within the firm’s top-line earnings. As in comparison with opponents, the corporate encountered difficulties, with a development price decrease than the typical amongst friends within the Well being Care sector.
Internet Margin: Teleflex’s monetary energy is mirrored in its distinctive web margin, which exceeds trade averages. With a exceptional web margin of 10.68%, the corporate showcases robust profitability and efficient value administration.
Return on Fairness (ROE): Teleflex’s ROE is under trade averages, indicating potential challenges in effectively using fairness capital. With an ROE of 1.77%, the corporate might face hurdles in reaching optimum monetary returns.
Return on Belongings (ROA): Teleflex’s monetary energy is mirrored in its distinctive ROA, which exceeds trade averages. With a exceptional ROA of 1.07%, the corporate showcases environment friendly use of belongings and powerful monetary well being.
Debt Administration: With a below-average debt-to-equity ratio of 0.4, Teleflex adopts a prudent monetary technique, indicating a balanced method to debt administration.
To trace all earnings releases for Teleflex go to their earnings calendar on our website.
This text was generated by Benzinga’s automated content material engine and reviewed by an editor.
Market Information and Knowledge delivered to you by Benzinga APIs
© 2024 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.